Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11406644 | 0.84 | HTT (0.51) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL20126281 | 0.83 | CA2 (0.35) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL16579166 | 0.83 | HTT (0.47) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL12154218 | 0.81 | KMT2A (0.61) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL20045170 | 0.81 | KMT2A (0.61) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL11298775 | 0.80 | KMT2A (0.51) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL27348977 | 0.80 | KMT2A (0.48) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL11416031 | 0.79 | HTT (0.46) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL11406313 | 0.79 | HTT (0.46) | HTTKMT2ASMN1; SMN2TDP1F2 | |
| SCHEMBL16579168 | 0.79 | HTT (0.43) | HTTKMT2ASMN1; SMN2TDP1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | HTT 2146/4885KMT2A 2766/4885SMN1; SMN2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.